Whatalane, Vinny
Around 2017 I was having neck and back problems and went in for a MRI. The next morning my personnel doctor (not back doc) called and told me I was loaded with Kidney Cysts on the right side and wanted them investigated. After a couple tests they determined they were liquid filled rather than solid so I was basically in the clear.
During this time period I researched autosomal dominant polycystic kidney disease (ADPKD) and like Kiwi said, there's nothing out there. I did come across Regulis and the trials they were performing with a drug called RGLS4326 was showing very good P1 and P2 control. I bought a couple thousand share on a hunch at $7 per share.
After they finished their 3rd MAD dose,which the results were fantastic, the bad news hit. Some rodents in their pre-clinical data have exhibited toxicity after 4 years, Of course the stock crushed.
Regulis responded that they were able to find the problem and promised a fix. Soon after they came out with RGLS8429 which they promised would be safe and more powerful.
Over the years the stock was sub $1 so they had a reverse split 1:10. Last fall evenafter the split the stock was at 50=60 cents and I accumulated over 100K more shares. Kripe the Companies Market Cap was at $14mil.
They just reported the 2nd co-hart a couple of weeks ago with great results along with a strategic buyers putting up $112 Mil for more shares. The shares immediately jumped to $2.80 and has leaked down to the lower $2 level.
Bet you never heard of that before, but someone likes it. The 3rd Co-hart is enrolled and results should be out june-july.
They are running the last dose at a fixed level and then will talk to the FDA.
Please note, one of my other favorite companies, Vertex just announced they want to enter the field.
Market Data 
Markets 
AI
